An in-depth look to EGETIS THERAPEUTICS AB NPV operating, investing, and financing activities

0ABW free cash flow for Q3 24 is -62.5 M SEK. For 2023, 0ABW free cash flow was -278.4 M SEK and operating cash flow was -278.4 M SEK.